Background
==========

It has been hypothesised that the slow progression to AIDS exhibited by HLA-B\*2705^+^HIV-infected individuals is due to the immunodominant B\*27-restricted response towards the p24 Gag epitope KK10 (Gag residues 263--272). This study aims to discern the contributing correlates of immune protection in HLA-B\*2705^+^HIV-infected individuals by comparing CD8^+^T cell epitope specificity, cytokine profile, granzyme production and the kinetics of epitope presentation.

Methods
=======

HLA-B\*2705 MHC-I tetramers were used to enrich CD8^+^T cell lines (\>98% specific), specific for the Gag epitope KK10, the Vpr epitope VL9, and Pol epitope KY9. We compared the polyfunctionality, proliferation, granzyme production and specific killing capacity of these epitope-specific CD8+ T cells. We also compared the polyfunctionality and granzyme production of epitope-specific CD8^+^T cells directly from ex vivo PBMCs. We then compared the ability of the different B\*2705-restricted epitope specific CD8^+^T cell lines (\>98% specific) to suppress viral replication in vitro. HIV-permissive cells expressing B\*2705 were infected and cocultured with the CD8^+^T cells, firstly by synchronized magnetofection™ and monitored over 24 hours and secondly by \'natural\' infection and monitored over 5--10 days.

Results
=======

The Gag KK10- and Pol KY9-specific CD8^+^T cells could elicit antiviral activity by 6 hours post-infection whereas the Vpr VL9-specific CD8^+^T cells didn\'t elicit antiviral activity until 18 hours post-infection. We observed a clear hierarchy of antiviral potency dictated by epitope or HIV protein specificity (Gag KK10\>Pol KY9\>Vpr VL9). Antiviral activity did not correlate with polyfunctionality, proliferation, granzyme production or killing capacity.

Conclusion
==========

The potent antiviral activity displayed by Gag KK10-specific CD8^+^T cells may be due to early presentation of Gag epitopes on HIV-infected cells. A vaccine which promotes CD8^+^T cells which can elicit early antiviral activity may help prevent viral dissemination during HIV infection and is a rational approach to vaccine design.
